Texas is currently home to 4891 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Dupilumab Effects Against Aeroallergen Challenge
Recruiting
The trial involves two interventions: (i) exposure to HDM in the ACC and (ii) administration of dupilumab/placebo for dupilumab.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/20/2025
Locations: Biogenics Research Chamber, San Antonio, Texas
Conditions: Asthma, Allergic
Canakinumab for the Prevention of Progression to Cancer in Patients with Clonal Cytopenias of Unknown Significance, IMPACT Study
Recruiting
This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets. In patients with CCUS, blood counts have been low for a long period of time. Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop. The com... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: UT Southwestern Medical Center at Dallas, Dallas, Texas
Conditions: Clonal Cytopenia of Undetermined Significance
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease
Recruiting
To learn if lifestyle changes (such as diet and exercise) combined with daily aspirin and vitamin D can affect the likelihood of advanced colorectal cancer coming back (recurring)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Colorectal Cancer, Colon Cancer
Contingency Management for Cannabis Use for Persons With HIV
Recruiting
The purpose of this study is to determine the feasibility and impact of 28-days of monitored abstinence from cannabis use on symptoms of depression and anxiety, pain, sleep, cannabis use withdrawal, HIV viral load and biomarkers of systemic inflammation among PLWH and who use cannabis regularly (weekly or more often). This will be a single arm pilot feasibility trial involving a contingency management program to induce cannabis abstinence. Specifically, the contingency management program will pr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Center for Neurobehavioral Research on Addiction, Houston, Texas
Conditions: Marijuana, HIV Infections
Prostate Cancer Upgrading Reference Set
Recruiting
Research repository designed to establish prostate cancer upgrading reference set and development of a risk prediction tool. Repository will include clinical information and biologics on a cohort of 240 men, to predict presence of high grade cancer at time of prostatectomy (removal of prostate) among patients with a low grade cancer diagnosis at time of biopsy.
Gender:
MALE
Ages:
Between 35 years and 99 years
Trial Updated:
02/20/2025
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Prostate Cancer
VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
Recruiting
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. VK2735 or matched placebo will be administered once daily.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Viking Clinical Site #104, Austin, Texas
Conditions: Weight Loss
Ligufalimab and Cadonilimab in Advanced Liver Cancers
Recruiting
The goal of this clinical trial is to find out if the combination of Ligufalimab and Cadonilimab are effective in treating advanced hepatobiliary cancers that have failed prior therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Dallas, Texas
Conditions: Generalized Anxiety Disorder
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled, flexible-dose study of the efficacy, safety, and tolerability of ITI-1284 in patients with agitation associated with Alzheimer's dementia
Gender:
ALL
Ages:
55 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Round Rock, Texas
Conditions: Agitation Associated With Alzheimer's Dementia
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Austin, Texas
Conditions: Generalized Anxiety Disorder
Study of Olutasidenib and Temozolomide in HGG
Recruiting
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
Gender:
ALL
Ages:
Between 12 years and 39 years
Trial Updated:
02/19/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Recruiting
The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Myelogenous Leukemia